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ABSTRACT
Treatment of cutaneous leishmaniasis (CL) is difficult due to the scarce number of drugs able to eliminate completely the 
intracellular form of the parasite. In the present study, the aim was to evaluate: i) phytochemical properties of extracts from 
Libidibia ferrea; ii) antileishmanial activity of extracts from L. ferrea against promastigotes and amastigotes of Leishmania 
(Leishmania) amazonensis and Leishmania (Viannia) guyanensis; iii) the effects of topical treatment using hydrogel containing 
active extract of L. ferrea on golden hamsters infected with L. (L.) amazonensis. Extracts from leaves, branches and fruits of L. 
ferrea were obtained with hexane and methanol and were tested by in vitro assays in promastigotes and murine macrophages J774 
experimentally infected with amastigotes of Leishmania. Groups of hamsters with CL received topical treatment with a formulation 
of extract (10%) hydrogels, 50 mg.day-1 for 40 days. In vitro activity of FrMeOH (methanolic extract from fruits without seeds) 
resulted in significant reduction of viable promastigotes of L. (L.) amazonensis (IC50 of 15.4 µg.mL
-1) and demonstrated inhibition 
potential of amastigote forms of  L. (L.) amazonensis and L. (V.) guyanensis and low cytotoxicity in macrophages. The overall 
data of topical treatment with extract hydrogels (GelFrMeOH) showed that lesion sizes were significantly reduced (42.78%), 
with low parasite burden by RT-qPCR and culture analysis by microscopy examination, and with histopathological findings 
such as lower inflammatory cell infiltration 40 days after treatment. Chemical analysis demonstrated FrMeOH contains high 
levels of phenolic compounds. The results indicate a possible alternative therapy for CL using phytotherapics.
KEYWORDS: cutaneous leishmaniasis, natural products, topical formulations, experimental treatment
Atividade anti-leishmania de extratos de Libidibia ferrea: desenvolvimento 
de testes in vitro e in vivo
RESUMO
O tratamento da leishmaniose cutânea (LC) é de difícil resultado, devido ao escasso número de fármacos capazes de eliminar 
completamente a forma intracelular do parasita. No presente estudo, objetivou-se avaliar: i) propriedades fitoquímicas dos 
extratos de Libidibia ferrea; ii) a atividade antileishmania de extratos de L. ferrea contra promastigotas e amastigotas de Leishmania 
(Leishmania) amazonensis e Leishmania (Viannia) guyanensis; iii) os efeitos do tratamento tópico utilizando hidrogel contendo 
extrato ativo de L. ferrea em hamsters dourados (Mesocricetus auratus) infectados com L. (L.) amazonensis.  Extratos de folhas, 
galhos e frutos de L. ferrea foram obtidos com hexano e metanol e foram testados por ensaios in vitro contra promastigotas e 
macrófagos J774 infectados com amastigotas de Leishmania. Grupos de hamsters infectados receberam hidrogel tópico com 
extrato (10%), 50 mg.dia-1 durante 40 dias. A atividade in vitro de FrMeOH (extrato metanólico dos frutos) mostrou redução 
significativa de promastigotas de L. (L.) amazonensis (IC50 de 15,4 µg.mL
-1), potencial de inibição de formas amastigotas de L. 
(L.) amazonensis e L. (V.) guyanensis (IC50 303,36 µg.mL
-1) e baixa citotoxicidade em células de macrófagos J774. Os resultados 
destacaram que as lesões cutâneas de animais que receberam tratamento com hidrogel + extrato (GelFrMeOH) apresentaram 
redução significativa (42,78%), menos úlceração e redução da carga parasitária detectada por RT-qPCR, microscopia e análise 
em cultura e alterações histopatológicas, como menor infiltrado inflamatório após 40 dias de tratamento. A análise química 
demonstrou que FrMeOH contém altos níveis de compostos fenólicos. Os resultados apontam para uma possível terapia 
alternativa para CL utilizando fitoterápicos. 
PALAVRAS-CHAVE: leishmaniose cutânea, formulações tópicas, produtos naturais, tratamento experimental
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Leishmaniasis is an infectious-parasitic disease caused by 
protozoa of different species of the genus Leishmania, which 
has the ability to invade and reproduce within the cells of the 
infected host’s immune system (Gontijo & Carvalho 2003; 
Pace 2014). When Leishmania promastigotes are introduced 
into the human skin, parasitism induces the proliferation of 
histiocytic cells and the phagocytosis of flagellates by these 
tissue macrophages that, besides not being able to destroy the 
parasites, still allow their multiplication within the digestive 
vacuoles (Sacks and Kamhawi 2001).
Cutaneous leishmaniasis (CL), although widely distributed, 
accounts for 1/3 of its occurrence in three epidemiological 
regions: the Americas, the Mediterranean and Central Asia 
(Alvar et al. 2012). Brazil is among the five countries with the 
highest number of cases of this endemic disease that represents 
a serious public health problem, with emphasis on the North, 
Midwest and Northeast regions (Costa 2005).
The drugs currently used against CL are the pentavalent 
antimonial salt as first choice drug, pentamidine and 
amphotericin B as second choice (Almeida and Santos et al. 
2011). However, all these present a number of problems, 
including parasite resistance and induction of side effects, and 
all the drugs currently available are parenteral administration 
(Silva-Lopez  2010).
A large part of the population, without access to medicines, 
seeks alternatives in popular medicine, with the therapeutic use 
of plants. Plant species produce a wide variety of secondary 
metabolites, with incomparable chemical and bioactivity 
diversity (Barreiro and Bolzani 2009), which has allowed the 
development of hundreds of pharmaceutical products (Oliveira 
et al. 2013).  Libidibia ferrea (Mart. Ex Tul.) L.P. Queiroz 
(Fabaceae) is a native tree of Brazil, it is commonly known 
as “pauferro” or “jucá”, found mainly in Brazilian savannah 
areas and the Amazon region, where it was introduced by 
Northeastern immigrants (Costa et al. 2015). Libidibia 
ferrea has a wide distribution, and many economic and 
pharmacological properties, being used from wood production 
to the afforestation of streets and avenues (Souza and Lorenzi 
2012). Pharmacological studies of extracts obtained from L. 
ferrea have demonstrated its biological anti-inflammatory 
(Carvalho et al. 1996), bactericidal (Sampaio et al. 2009), 
hypoglycemic and antioxidant potentials (Batubara et al. 2009) 
and healing activity (Oliveira et al. 2010). Chemical studies with 
this species have shown the presence of phenolic compounds 
with possible pharmacological applications, such as chalcones 
and polyphenols (Nakamura et al. 2002; Nozaki et al. 2007).
Topical drug delivery offers numerous advantages for the 
treatment of CL. The hydrogels used in topical treatments 
have similar flexibility to natural tissues due to the high water 
content, which minimizes the irritation of the membranes or 
the tissues neighboring the application site (Koop 2012), with 
a better patient compliance.
The objective of this study was to evaluate the chemical 
properties and antileishmanial activity of extracts obtained 
from L. ferrea against promastigotes and amastigotes of 
Leishmania that cause cutaneous leishmaniasis and to study 
the effect of topical treatment with hydrogels containing 




Samples of Libidibia  ferrea (leaves, branches and fruits) 
were collected in Manaus, Amazonas, Brazil (3°4’34”S 
60°0’11”W). A prepared voucher specimen was identified by 
Dr. Mike Hopkins, and deposited in the Herbarium of the 
National Institute of Amazonian Research (INPA) under the 
identification number 246150. Part of the plant material was 
dried in a forced circulation oven, with temperature below 
45°C. After drying, the parts (leaves, branches and fruits 
without seeds) were pulverized and extracted with hexane and 
methanol solvent (VETEC®). Three extractions were done 
with each solvent using ultrasound bath for 20 min at each 
extraction. After ultrasound bath, the material was filtered, 
and concentrated on rotatory evaporator (Büchi®).
Phytochemical prospection
Crude extracts were submitted to a series of phytochemical 
characterization reactions to detect the presence of secondary 
metabolites as phenolic compounds (precipitation reaction with 
ferric chloride), flavonoids (magnesium metal in hydrochloric 
acid), triterpenes (Liebermann-Burchard reaction), alkaloids 
(Dragendorff) and characterization of saponins (foam index), 
according to the methodology described by Simões et al. (1999).
Determination of phenolics and flavonoids
For the dosage of total phenolics, extracts (1.0 mg ml-1) 
were dissolved in methanol or isopropanol (Prolabo®) and 
diluted in 5% triethanolamine and FeCl3 (0.165%).  The 
reading of absorbance was performed on a spectrophotometer 
(510 nm), and the reactions were made in triplicate and 
compared with the standard curve of pyrogallol (Merk®). For 
the determination of total flavonoids, the extracts were dissolved 
in methanol or isopropanol and diluted in sodium acetate (0.1 
M) and 10% AlCl3. The reading of absorbance was performed 
by spectrophotometer (415 nm) and reactions were made in 
triplicate and compared to standard curve of quercetin and 
naringenin (Merk®). The TPC (total phenolic content) and 
TFC (total flavonoid content) of the extracts was represented as 
milligrams of standard equivalents per gram of dry extract (mg 
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pyrogallol or quercetin or naringenin / g extract), according to 
the calibration curve where a = linear coefficient of pyrogalol/
quercetin/naringenin curve and b = slope of the curve).
Origin and maintenance of parasites
We used Leishmania (L.) amazonensis (MHO/BR/2006/
IM5584), Leishmania (V.) guyanensis (MHO/BR/95/M4147) 
characterized, cryopreserved and kept in the Laboratory of 
Leishmaniasis and Chagas´s Disease, National Institute of 
Amazonian Research - INPA. The parasites were grown in 
Novy-MacNeal-Nicolle medium (NNN) and culture expanded 
in complete RPMI medium 1640 (Himedia), supplemented 
with 10% inactivated fetal calf serum (iFCS) and gentamycin 
(40 µg.mL-1) and cryopreserved in ultra-freezer at −80 °C. 
Murine macrophages (lineage J774) were maintained in 
complete (Himedia®) in culture bottles in an oven at 37°C. 
In vitro promastigote assay
The assays were performed in 96 well plates using 
promastigotes in late log phase (106 cells.mL-1), according 
to Fumarola et al. (2004). The extracts were diluted in 3% 
v/v of dimethyl sulfoxide (DMSO, Vetec®) and Schneider’s 
Drosophila medium, filtered through 0.22 µm Millipore 
membranes in a sterile condition.  Extracts of L. ferrea were 
evaluated at concentrations of 32 to 500 µg.mL-1. Controls 
of assay were pentamidine (Pentacarinat®) and 3% v/v of 
solvent DMSO was used as a negative control. The activity of 
the samples was evaluated by growth inhibition and mortality 
in periods of 24, 48 and 72 hours, at 25° C. Bioassays were 
made in triplicates and repeated twice. Parasite viability was 
quantified with hemocytometer. 
Cell culture and cytotoxicity tests
Macrophages were placed in 24 mL of 105 cells.mL-1 
of macrophage lineage J774 that were pre-cultured in 24-
well polyethylene plates containing RPMI 1640 medium 
supplemented with 10% of  iFCS for 24 h  at 37°C, and 
after that they were placed in L. ferrea extracts. Incubation 
of macrophages was oven at 37°C for 48 h in the presence 
of the samples and MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-
diphenyl-2H-tetrazolium/Roche®) reagent. Macrophages were 
incubated for another 12 h and then the colorimetric readings 
were made with a spectrophotometer (Bio-Tek®) using the 
wavelength of 590 nm.
Amastigote-macrophage assay
Culture of macrophage lineage J774 (105cells.mL-1) in 24-
well plate was infected with a number of 106 promastigotes.
mL-1 (1:10 cell/parasite) for four hours. Macrophages infected 
were incubated in the presence of L. ferrea extracts that showed 
higher antileishmanial potential against promastigotes of 
L. (V.) guyanensis and L. (L.) amazonensis and little or no 
cytotoxicity. After 48 h of incubation at 37°C, the wells were 
washed, glass cover slips were removed and the infected cells 
fixed and stained with Panotic (Laborclin®). We quantified 
by optical microscopy the number of infected macrophages 
(200 macrophages per slide/replicate), and the number of 
amastigotes per macrophage. 
In vivo experiments
Origin and infection of animals: experimental animals 
used were 36 golden hamsters (Mesocricetus auratus), specific-
pathogen–free, males and adults coming from and kept in the 
Experimental Care Center of INPA. Hamsters were housed in 
stainless steel cages in rooms conditioned with photoperiod and 
controlled temperature (22-24 °C) and humidity (50-60%) in 
feeding conditions ad libitum and free access to tap water. This 
study was approved under protocol number 009/2012 and 
carried out according to the regulations and recommendations of 
the Animal Research Ethics Committee - CEUA of INPA. The 
animals were separated into experimental groups and infected 
in the nose with 100 µL of L. (L.) amazonensis (106 cells.mL-1). 
The animals remained under supervision until the appearance 
of the lesions. Treatment with the hydrogel commenced 22 
days after infection, and treatments were applied to the lesions 
once daily for 40 days, in a dose of 50 mg.day-1. Production 
of the formulations: hydrogel was prepared using macrogols 
(polyethylene glycols) in hydrophilic bases, in aqueous system as 
a cosolvent, and added to a base 10% of active extract FrMeOH, 
designated as GelFrMeOH. The hydrogel base with no extract 
was used as control placebo (GelPla). Experimental protocol: the 
animals were randomly allocated into four treatment groups: 
I – Infected untreated control group; II - Infected treated group 
with GelFrMeOH; III - Infected treated group with GelPla; IV 
- Infected treated group with Glucantime® intramuscular (IM) 
in a dose of 20 mg(Sb5).kg.day-1 .  
Evaluation of treatment effects
Clinical evaluation: daily evaluation to determine total lesion 
volume using pachymeter (Zaas Precision®) to analyze the 
progression of the lesion. Lesions were also photo documented 
for morphological evolution. Euthanasia: The animals were 
euthanized with Euthanyle® (sodium pentobarbital - phenytoin 
sodium) in accordance with CEUA/INPA. Parasitological studies: 
lesions were obtained of groups in two different experimental 
times: i) from animals sacrificed at the end of treatment (40th 
day); ii) from animals sacrificed 20 days after treatment (60th 
day). A tissue sample sectioned from the lesion area of each 
animal was used for an imprint on glass slides. The slides were 
stained with Giemsa (Sigma), and the infectivity index was 
determined by multiplying the percentage of macrophages that 
had at least one intracellular parasite by the average number of 
intracellular parasites per infected macrophage (200 cells were 
examined/animal). Viability of parasites in culture medium: 
Tissue fragments of lesions were cultivated in NNN medium 
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for eight days at 25 oC to observe the parasite viability. Parasite 
quantification by q-PCR: fragments of approximately 10 mg 
were transferred to microtubules (Eppendorf®) and then the 
DNA extraction procedure was performed using the Wizard® 
Genomic DNA Purification Kit (Promega), homogenized 
nuclear lysis solution, Proteinase K (20 mg / mL) and RNAse, 
according to the manufacturer’s instructions. For the q-PCR, 
reactions were prepared with a final volume of 25 µL with 
oligonucleotides at 100 nM and SYBR Green PCR Master Mix 
(Applied Biosystems). For the experiment, a standard curve was 
obtained. The thermal cycler used was the Rotor-Gene Q model 
(QIAGEM). Calculation of the absolute numbers of copies for 
samples of each assay was done taking into account the efficiency 
(E = 1.19248 (* = 10(-1/m) -1) of the reaction. Histopathological 
study: Tissue sections from skin lesions were used for histological 
study. The tissues were fixed with 10% buffered formalin and 
embedded in paraffin. Susequently, the sections were stained 
using hematoxylin and eosin (HE), and then they were dried 
overnight. The stained tissues were microscopically examined 
and the most detailed and clear tissue slides were chosen. 
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 
software (version 6.0 for Windows). The number of live cells was 
used to calculate by linear regression and to calculate the IC50 
values (Inhibitory Concentration for 50% of the live parasite). A 
one-way ANOVA statistical test was used to assess the significance 
of the differences between the various groups followed by Tukey’s 
test to compare the means of different treatment groups, with 
95% confidence to be considered significant. 
RESULTS
Methanolic extracts from leaves, branches and fruits of 
Libidibia ferrea when revealed with ferric chloride showed 
strong reaction and well-marked bands, especially FrMeOH 
extract (Table 1). Dragendorff’s reagent was the only that 
showed no stain to extracts, indicating low concentration or 
absence of alkaloids (Table 1). The extract with the highest 
income was the FrMeOH, containing up to 40% yield (Table 
2). The hexanic extracts, however, had very low income, 
where all parts extracted with hexane showed yield below 2% 
(Table 2). Methanolic extracts showed a high concentration 
of phenolic compounds. The most pronounced values of TPC 
were found in the methanolic extract from fruits without seeds 
(514.65 mg pyr/g dry extract) and leaves (494.20 mg pyr/g 
dry extract) (Table 2). Total flavonoid content (TFC) ranged 
from 5.67 to 69.35 mg quercetin/g of dry extract, and highest 
value was found in FrMeOH (Table 2).
Different parts of the same individual may have a large 
variation in the content and concentration of secondary 
metabolites, and thus may have a different biological activity. 
Table 3 shows the IC50 values calculated from results of 
extracts against Leishmania promastigotes. It was observed 
that the most promising extract was the methanolic extract 
of fruits (FrMeOH) with IC50 15.04 µg.mL
-1 against L. (L.) 
amazonensis (Table 3). However, this extract showed low 
activity against L. (V.) guyanensis (173.11 µg.mL-1).  The 
second extract with greater activity was the hexanic extract 
of the leaves (LeHex), which showed activity against L. (L.) 
amazonensis, with IC50 value of 53.09 µg.mL
-1. Hexanic extracts 
from fruits and branches of L. ferrea showed no activity at the 
highest concentration tested for L. (L.) amazonensis. However, 
the LeHex extract showed low antileishmanial activity when 
evaluated against their potential L. (V.) guyanensis (Table 3). 
For L. (V.) guyanensis, inhibitory effects on promastigotes were 
observed for methanolic extract of the leaves (LeMeOH), with 
IC50 value of 129.42 µg.mL
-1. EpMeOH exhibited an IC50 of 
173.11 µg.mL-1 against promastigotes of L. (V.) guyanensis.
Among the most promising extracts (FrMeOH, LeMeOH 
and LeHex), FrMeOH extract from L. ferrea  was less cytotoxic 
with IC50 above 500 µg.mL
-1. Even when higher doses were 
used, such as 500 µg.mL-1 of FrMeOH extract, viable cells 
only decreased 18.13% (data not shown). For this reason this 
extract was selected for evaluation of antileishmanial potential 
in intracellular forms in infected macrophages. However, 
cytotoxicity in macrophages was observed when  LeMeOH and 
Table 2. Total phenolic content (TPC) and total flavonoid content (TFC) in 
extracts of leaves (Le), branch (Br) and fruits without seeds (Fr) from Libidibia 
ferrea  obtained with hexane (Hex) or methanol (MeOH). Pyr = Pyrogallol; 
Quc = Quercetin; Nar = Naringenin. Values are means ± standard deviation.




LeHex 128.61 ± 18.50 6.76 ± 0.76 5.27 ± 0.09 1.51
LeMeOH 494.20 ± 17.20 22.10 ± 1.40 19.1 ± 0.60 15.45
BrHex 43.84 ± 8.54 5.67 ± 0.98 3.84 ± 0.18 1.50
BrMeOH 322.07 ± 40.22 32.60 ± 0.91 18.76 ± 0.17 12.50
FrHex 167.59 ± 16.08 15.07 ± 1.20 15.82 ± 0.11 0.18
FrMeOH 514.65 ± 23.31 69.35 ± 3.87 64.11 ± 1.19 40.42
Table 1. Phytochemical analysis of Libidibia ferrea leaf (Le), branch (Br) and 
fruit without seeds (Fr) extracts from hexane (Hex) or methanol (MeOH).
Phytochemicals
Extract Phenolic Flavonoid Triterpenes Alkaloids Saponins
LeHex + + + - -
LeMeOH ++ ++ + - +
BrHex + + + - -
BrMeOH ++ + + - +
FrHex + + + - +
FrMeOH +++ ++ + - +
+ = present; - = absent.
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LeHex were tested in 500 µg.mL-1. IC50 values of cytotoxicity 
for these extracts were 281.89 and 285.28 µg.mL-1.  
Thus, the anti-amastigote effects of FrMeOH on in vitro 
infected-macrophages were tested. A screening showed that 
500 µg.mL-1  of FrMeOH when incubated with amastigotes 
of  L. (V.) guyanensis inhibited 62% of amastigote survival in 
comparison to controls. The IC50 for amastigotes of L. (V.) 
guyanensis was 330.36 µg.mL-1.  Activity against amastigotes of 
L. (L.) amazonensis was observed in  500 µg.mL-1 of FrMeOH, 
with reduction of 54% of infected macrophages. 
The parameters analyzed to evaluate the effects of 
treatments applied by topical administration on the lesions 
caused by L. (L.) amazonensis in hamsters allowed to follow the 
clinical evolution during the treatment, and the influence on 
parasites and tissues at the end of the 40-day treatment. The 
clinical evolution of lesion volumes is an important aspect to 
be evaluated, since cutaneous leishmaniasis (CL) can produce 
in the infected hamsters the development of histiocytic lesions, 
with broad tissue growth similar to benign lesions that develop 
in a chronic way to ulcers or nodular lesions. This experiment 
showed a 445.94% increase in the total lesion volume in the 
hamster noses of the control group compared to the first day 
of treatment.
During the clinical analysis we observed progressive 
growth in the size of lesions. The group that received treatment 
with the pentavalent antimonial Glucantime® (20 mg (Sb5) 
kg.day-1) IM showed statistical differences with the negative 
control group (infected untreated control group) at the 14th 
day of treatment, with P = 0.0138. The statistical difference 
between the groups increased by the 20th day (P < 0.001). 
The animals continued to receive antimonial treatment until 
the 40th day of treatment, even though the reduction occurred 
after 20 days of treatment. At the end of treatment, a 43.42% 
reduction in lesion volume was observed in relation to the 
start of treatment (Figure 1).
The group receiving topical GelFrMeOH treatment 
showed constancy of the lesion volumes, not allowing the 
increase observed in the untreated group (Figure 1). There 
was a statistical difference between the lesion volumes of 
the GelFrMeOH group and the untreated group by the 
14th day, with P = 0.0218. Statistical differences between 
the group treated with GelEpMeOH and the untreated 
group increased with continuity of treatment until reaching 
maximum differences in lesion size by the 24th day of 
treatment (P < 0.001). Animals treated with GelEpMeOH 
showed 42.78% reduction in lesion volume after 38 days of 
treatment compared to the first day of treatment (22th day 
post-infection).
However, the group that received topical gel excipients 
(GelPla) also showed significant difference between the means 
of lesion size when compared to the group at the 20th day of 
treatment (P = 0.0178). The mean values of the lesions of the 
GelPla group assume an intermediate position in the graph 
(Figure 1), showing difference between the control group and 
the groups treated with GelFrMeOH and with antimonial 
(Glucantime®). The difference between the GelFrMeOH 
group and the GelPla group occurred after the 30th day of 
treatment (P = 0.0411), and the difference increased with 
treatment time, reaching maximum difference on the last 
(40th) day of treatment (P = 0.0015). On the last day of 
treatment, mean lesions of the GelPla group corresponded to 
a 241% increase compared to day 0 of the treatment.
Lesions of the animals of the group that did not receive 
any treatment increased gradually during the experimental 
time, reaching indices superior to 400% of increase. The 
lesions of the group that received topical treatment with 
GelPla also increased, but in smaller proportions than in the 
Table 3. Anti-leishmanial activity in promastigotes of Leishmania spp. and 
IC50 values of Libidibia ferrea extracts of leaves (Le), branches (Br) and fruits 
without seeds (Fr) obtained with hexane (Hex) or methanol.
IC50 (µg.mL-1 )
Samples L. amazonensis L. guyanensis
LeHex 53.09 ± 4.48 > 500
LeMeOH 307.46 ± 2.49 129.42 ± 2.79
BrHex > 500 > 500
BrMeOH > 500 178.38 ± 2.99
FrHex > 500 > 500
FrMeOH 15.04 ± 2.54 173.11 ± 1.86
Quercetin 18.94 ± 0.54 24.61 ± 0.39
Naringenin 6.02 ± 0.81 14.48 ± 0.75
Pentamidine 1.62 ± 0.10  ± 0.07 Figure 1. Effect of topical treatment on lesion of golden hamsters 
(Mesocricetus auratus) infected with Leishmania (Leishmania) amazonensis, 
using 50 mg.day-1 of hydrogel with extract from Libidibia ferrea. Negative 
Control: animals infected and untreated. Positive control: animals treated with 
Glucantime® IM 20 mg(Sb5).kg.day-1. The data represent the mean ± SD. 
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control group, with an increase of 2.4 times its total volume. 
Lesions in the GelFrMeOH and Glucantime® treated groups 
reduced their total volume by more than 40%. There was 
presence of scar ulceration of varying diameter and magnitude 
in animals of control group (without treatment) as shown in 
Figure 2. Lesions of the group that received treatment with 
GelFrMeOH continued with its nodular aspect, or regression 
of the nodule, presenting 11% of animals with scar ulceration. 
The animals treated with GelPla had nodular lesions at the 
beginning, but 67% of the lesions presented ulceration. 
Animals treated with IM antimonial (Glucantime®) did not 
present ulceration until the end of treatment.
Parasitological studies of lesions were obtained of groups 
in two different experimental times: at the end of treatment 
(40th day) and 20 days after treatment (60th day). The parasite 
viability verified by the NNN culture was semi-quantitative, 
and revealed the presence of higher scores of viable flagellate 
parasites in the cultures from fragments of the untreated 
group (score > 2). After 40th day, the lowest score was of 
the positive control (treatment with antimonial), with few 
viable parasites. Treatment groups GelFrMeOH and GelPla 
presented few viable parasites (score < 1) (Figure 3). On the 
60th day the untreated group continued with high viability 
Figure 2. Clinical aspect of macroscopic lesions of  Golden Hamster 
(Mesocricetus auratus) nose infected by Leishmania (Leishmania) 
amazonensis. Image of 30rd day of treatment. A – animal treated with 50 
mg.day-1 of hydrogel with 10% of extract from Libidibia ferrea. B - animal treated 
with 50 mg.day-1 of hydrogel excipients. C - animal treated with Glucantime® 
IM 20 mg(Sb5).kg.day-1. D – Control Group:  animal infected and untreated. 
This figure is in color in the electronic version.
Figure 3. Parasitological studies of material from lesions of golden hamster (Mesocricetus auratus) nose infected by Leishmania (Leishmania) amazonensis. 
A - at the end of treatment (40th day). B - 20 days after treatment (60th day). 1 - Parasite index counted by imprinting lesions fragments stained with Giemsa 
and counted in 1000 X. 2 - Parasite quantification by q-PCR. Control: animals inoculated but without topical treatment. The data represent the mean ± SD. *P 
< 0.05 when compared with all groups.
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(score >3) of parasites, while viable parasites were present in 
the group treated with Glucantime®, GelFrMeOH and GelPla 
with score = 2. 
The evaluation of the parasite load by impression smears 
obtained after 40th day of treatment showed statistical 
differences between the GelFrMeOH and GelPla groups (P 
< 0.0001), the GelFrMeOH group and the untreated group 
(P < 0.0001). The group that received antimonial treatment 
(Glucantime®) also presented statistical difference compared 
with the negative control (P = 0.0086). Summarizing these 
results, the mean values visualized for the groups treated with 
GelFrMeOH, and Glucantime® showed values well below those 
found in their respective placebos and in the negative control. 
After 60 days of evaluation (20 days post treatment), only the 
GelFrMeOH group showed difference between GelPla (P = 
0.005) and the group that received no treatment (P = 0.0004). 
We observed significant decrease in the parasite density in the 
group treated with GelFrMeOH when compared with their 
corresponding infected control group. 
Parasite quantification by the real-time PCR (q-PCR) 
method, which is based on the detection of Leishmania 
DNA present in the lesions, showed that all the groups that 
received some treatment presented statistical differences 
in the concentration of parasite DNA when compared to 
the untreated group of samples obtained on the 40th day of 
treatment (Figure 3). The groups that received treatment with 
GelFrMeOH presented the lowest concentrations (<0.01), 
presenting P = 0.0276. GelPla also showed difference in 
relation to the untreated group (P = 0.0279). The group 
treated with pentavalent antimonial (Glucantime®) had values 
lower than 1.62 parasitic load and P = 0.027 compared to the 
untreated group. However, there was a change in the profiles 
of the parasite concentration in samples from the animals that 
remained for 20 days at the end of treatment (60th day). Mean 
values increased for the Glucantime® treated group (> 14,000) 
and decreased for the untreated group (287). The lowest values 
were found for the GelFrMeOH group (< 4.0) and the GelPla 
group (5.88). All groups presented statistical differences when 
compared to the group treated with Glucantime® (p < 0.05). 
The different diagnoses for parasite load (Figure 3) seem 
to converge on the results of the parasitism reduction in the 
lesions of treated animals with gel containing the extract 
more efficiently than the animals treated with Glucantime®, 
mainly when comparing the results after 20 days of the end 
of the treatment.
The dermal inflammatory pattern and cell population 
were estimated histologically in sections stained with 
HE. Pathologically, in the control group (untreated) the 
epidermis showed ulceration overlying connective tissue 
heavily infiltrated by inflammatory cells, predominantly 
composed of histocytes, and the most common lesion pattern 
was perifollicular dermatitis, mainly around the capillary 
Figure 4. Light micrograph of nose skin of infected hamster (Mesocricetus 
auratus) with Leishmania (Leishmania) amazonensis showing infiltration of 
connective tissue by acute and chronic nonspecific inflammatory cells (H&E 
X400). A – Control Group:  animal infected and untreated.  B - animal treated 
with Glucantime® IM 20 mg(Sb5).kg.day-1. C – animal treated with 50 mg.day-1 
of hydrogel with 10% of extract from Libidibia ferrea. D - animal treated with 50 
mg.day-1 of hydrogel excipients. This figure is in color in the electronic version.
isthmus (Figure 4A). The inflammatory infiltrate extended 
to the region of the sebaceous gland, obliterating it in some 
cases. Diffuse or perivascular infiltrate usually accompanied 
perifollicular inflammation. The intensity of the inflammatory 
infiltrate is shown in Figure 4A where the invasion at the 
border of the fibrous perichondrium of the nasal cartilage 
can be observed. Macrophages were predominant, with a 
discrete presence of lymphocytes and plasma cells. Isolated 
neutrophils were also observed in some laminae. In the 
animals treated with Glucantime® (positive control), the 
dermatitis was mild, papillary dermis, with a low mononuclear 
infiltrate, not extending to the hair follicles. Sebaceous adenitis 
was not observed in the analyzed samples (Figure 4B). The 
samples obtained from the animals of the GelFrMeOH group 
showed slight infiltration of inflammatory cells and absence 
of amastigote forms of parasites (Figure 4C), whereas in the 
GelPla group there was an intense and diffuse infiltration of 
inflammatory cells (Figure 4D). In the placebo group, we 
observed infiltration of epithelioid cells, lymphocytes and 
neutrophils in addition to plasma cells. In some areas, adenitis 
of the sebaceous gland and granulomatous area.
DISCUSSION
The search for new treatments that are less toxic and 
easily bioavailable to treat poor population, generally more 
affected by leishmaniasis, is imperative, and natural products 
are potential sources of a great variety of biological activity 
substitutes (Oliveira et al. 2013). In this study, promising 
results obtained are similar to other ones from natural sources, 
as reported by Singh et al. (2012). Nevertheless, no natural-
based therapy for the treatment of CL is currently advocated 
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by health agencies in countries where leishmaniasis is endemic 
(Croft et al. 2006).
Prospection of natural products present in Libidibia 
ferrea extracts showed that phenolic compounds are the 
most representative, corroborating the findings of Ueda et 
al. (2011). Phenolic compounds derived from vegetable 
products are recognized to have antioxidant activities that act 
as auxiliaries in the functioning of the endogenous immune 
system (Hakime-Silva et al. 2013). Among the chemical 
components described in the literature for the genus Libidibia 
the presence of polyphenols is highlighted. Another class 
of substances that have been characterized are terpenoids, 
which are usually extracted with low polarity solvents (Dias 
et al. 2013). 
Port’s (2011) noted in a study of nine species of plants, 
prepared as teas, that higher levels of phenolic compounds were 
present in L. ferrea. Gallic acid and ellagic acid were quantified 
by HPLC in extracts of the fruits of L. ferrea by Cunha et al. 
(2012), indicating values above 2.49% of gallic acid and 5.89% 
of ellagic acid. These values can indicate a high level of phenolic 
compounds produced by L. ferrea even in individuals present 
in regions of different environmental conditions. 
In the present study, we observed that this extract also 
showed high concentrations of phenolics and flavonoids, 
classes of metabolites already widely described and isolated 
from the genus Libidibia, as gallic acid and methyl-3,4,5-
trihydroxybenzoate (Nakamura et al. 2002; Das et al. 
2010). From stem extract of L. ferra chalcone pauferrol A, a 
topoisomerase II inhibitor, was isolated (Nozaki et al. 2007). 
Different structures of metabolites of the phenolic class have 
already shown interaction in topoisomerase II of Leishmania 
species (Sen and Chattergee 2011), being this a possible 
mechanism of inhibitory action.
Leaves of Tephrosia cinerea (L.) Pers., a species of the 
Fabaceae family, showed IC50 of 43,6 µg.mL
-1 against L. 
amazonensis in a study of activity from species used as 
medicinal plants, and it was one of great results of Bezerra et 
al. (2006). Previous studies have shown biological activities 
of the extracts of fruit and stem L. ferrea, such as anti-
inflammatory (Carvalho et al. 1996; Pereira et al. 2012), and 
antimicrobial, whereas fruit extract can inhibit in vitro growth 
of oral pathogens (Sampaio et al. 2009), and antioxidant (Silva 
et al. 2011), but this was the first screening with different 
extracts obtained from L. ferrea evaluated for Leishmania 
species. However, previous studies showed that the topical 
use of L. ferrea ointment was significantly efficient to help 
healing cutaneous wounds in goats (Oliveira et al. 2010). 
Evaluating the chemical results together with the biological, 
the methanolic extract obtained from fruits without seeds is 
the most promising for future studies, with high extraction 
yield, high content of phenolics and flavonoids, activity against 
promastigotes of L. (V.) guyanensis and L. (L.) amazonensis 
and amastigotes of L. (V.) guyanensis and low cytotoxicity 
in J774 macrophages. The extract FrMeOH showed high 
concentrations of phenolics which have shown inhibitory 
activity on DNA synthesis, by interactions with topoisomerase 
II of Leishmania species (Sen and Chatterje 2011). 
Studies that seek new therapeutic forms against cutaneous 
leishmaniasis evaluate several parameters to determine the 
efficacy of the compound and its use (Schwartz et al. 2014). 
Comparison between the clinical results observed in animals 
that received treatment with hydrogel + 10% of methanolic 
extract of L. ferra and the untreated group showed strong 
evidence of the activity of the formulation on the development 
and evolution of the lesions, both by controlling the increase in 
the total volume of the lesion and other clinical aspects. In the 
groups that received the hydrogel, the lesions did not present an 
increase in their volume, with statistically significant differences 
when compared to the control group, and this evolution was 
similar to the group that received standard drug treatment 
(Glucantime®). In addition, the hydrogel with FrMeOH 
appears to have produced action in preventing the formation 
of ulcers in the lesions, according to the clinical evaluations. 
Promising results were found employing second choice drugs to 
the treatment of CL, as topical formulation with paromomycin 
sulfate, that was used topically twice a day for 4 weeks to treat 
L. major lesions on BALB/c mice, and the results showed a 
significantly smaller lesion size in the mice in the treated groups 
than in the mice in the control groups (Bavarsad et al. 2012).
Several parameters were analyzed to allow a more accurate 
diagnosis of the parasite load present in the lesions of hamsters 
(M. auratus), both at the end of the treatment and after a 
period without receiving it. Summary results showed that 
there is a correlation between the different methods applied 
(tissue/histological aspect, detection of the presence of parasitic/
molecular DNA and parasitological aspects), as it was detected 
in Swiss albino mice model infected with L. major (Eissa et al. 
2011). Hydrogel treatment presented parasite load well below 
the other treatments, when the lesions were analyzed at the end 
of the treatment. However, there was an increase, although lower 
than in the negative control and also in the group treated with 
Glucantime®, regarding the presence of parasites after 20 days 
without receiving treatment. Hamsters treated with a topical 
formulation with pentamidine also showed viable parasites 
after end of treatment (Comandolli-Wyrepkowski et al. 2017).
The effect observed for the FrMeOH hydrogel can be 
explained by the penetration of the active principle and its 
diffusion rate, parameters that should be analyzed in future works. 
The question of penetration is one of the factors that determines 
efficacy in the treatment of tegumentary leishmaniasis, since the 
active principle must act in deeper tissues of the dermis, where 
many infected macrophages are located (Garnier et al. 2002). The 
other relevant question is the intrinsic antileishmanial activity of 
the sample (Schwartz et al. 2014), which was observed for the 
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FrMeOH extract in in vitro systems. In relation to hydrophobicity 
characteristics, it was added in hydrogel formulations due to its 
more hydrophilic character, increasing the interaction with the 
excipients, according to recommendations of the pharmaceutical 
technology (Nagelreiter et al. 2015).
A study using chitosan hydrogel with the antibiotic 
paromomycin in the treatment of experimental CL also found 
promising results in lesions caused by L. (L.) amazonensis 
(Gonçalves et al. 2005). The hydrogels used in topical treatments 
have similar flexibility to natural tissues due to the high water 
content, which minimizes the irritation of the membranes or 
tissues neighboring the application site (Koop 2012).
Topical therapies are more attractive options, offering 
reduced systemic toxicity and ease for the patient himself. 
However, when analyzing the therapeutic efficacy for the 
treatment of CL in a more comprehensive way, one should 
not only verify the elimination of the parasite, but also look 
in an integrated manner at the questions related to the aspects 
that involve the anti-inflammatory reactions and the healing 
capacity, thus promoting tissue repair and re-epithelialization, 
avoiding secondary infections (Schwartz et al. 2014). Thus, 
this work allowed to verify the activity against the parasites 
and the effects on an experimentally infected host model, and 
to indicate a promising herbal treatment in the topical form 
of a hydrogel for the treatment of CL. 
CONCLUSIONS
The methanolic extract of the fruits (FrMeOH) obtained 
from L.  ferrea is the most promising, since it has in vitro 
activity against promastigotes and amastigotes of L. (L.) 
amazonensis and L. (V.) guyanensis and does not present 
cytotoxicity in macrophages J774. This extract is obtained 
with high values of yield of the vegetal material, besides 
having the highest values of phenolics between the extracts 
and high concentrations of flavonoids. The animals treated 
with the hydrogel containing the L. ferrea MeOH extract 
of fruits, after 40 days of treatment, presented reduction of 
lesion volume, decreased inflammation in the lesion region 
and lower parasitic load when compared to infected animals 
untreated, or that received only the gel without the extract.
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